The identification of effective signatures is crucial to predict the prognosis of acute myeloid leukemia (AML). The investigation aimed to identify a new signature for AML prognostic prediction by using the three gene expression (OCT4, POU5F1B and BMI1P1). The expressions of genes were obtained from our previous study. Only the specimens in which three genes were all expressed were included in this research. A three-gene signature was constructed by the multivariate Cox regression analyses to divide patients into high-risk and low-risk groups. ROC analysis of the three-gene signature (AUC = 0.901, 95% CI: 0.821 - 0.981, P < 0.001) indicated that it was a more valuable signature for distinguishing between patients and controls than any of the three genes. Moreover, white blood cells (P = 0.004), platelets (P = 0.017), percentage of blasts in bone marrow (P = 0.011) and complete remission (P = 0.027) had significant differences between two groups. Furthermore, high-risk group had shorter leukemia free survival and overall survival than low-risk group (P = 0.026; P = 0.006), and the three-gene signature was a prognostic factor. Our three-gene signature for prognosis prediction in AML may serve as a prognostic biomarker.

This content is only available as a PDF.
This is an Accepted Manuscript; not the final Version of Record. You are encouraged to use the final Version of Record that, when published, will replace this manuscript and be freely available under a Creative Commons licence.